Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Chemotherapy-induced Neutropenia 4Neoplasms 3Lung Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Carcinoma, Renal Cell 1

Interventions

Etoposide 4Carboplatin 4atezolizumab 3pembrolizumab 2Radiotherapy 2tislelizumab 1sintilimab 1irinotecan sucrosofate 1durvalumab 1camrelizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1Observation 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Epirubicin 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Cancer Extensive Stage × NPI 2358 × Clear all
NCT05745350 2025-02-11

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡